ArticleDiscover oncology2026
Global, regional, and National burden of urologic neoplasms from 1990 to 2021 and future projections to 2050, a comprehensive analysis for global burden of disease.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrologic neoplasms are considered to pose a serious threat to patients’ lives and quality of life. Analyzing and describing the global disease burden of urologic neoplasms is necessary.
methodsThe Global Burden of Disease (GBD) 2021 was utilized to obtain and analyze the age-standardized incidence rate (ASIR), age-standardized death rate (ASDR), and disability-adjusted life years (DALYs) for urologic neoplasms from 1990 to 2021. Additionally, risk factors contributing to urologic neoplasms were estimated, and the model was utilized to predict the global burden over the next 30 years.
resultsA continuous growth trend in the number of urologic neoplasm cases worldwide was observed. However, the ASDR and DALYs were found to be stable or decreasing. Trends vary by gender, age, and socio-demographic index (SDI), with a greater burden of urologic neoplasms typically observed in older men. Moreover, risk factors for kidney cancer include tobacco use, high body mass index, and occupational hazards, whereas bladder cancer risk factors consist of tobacco use and elevated fasting plasma glucose levels. It is estimated that by 2050, the global incidence of urologic neoplasms will exhibit a relatively stable trend, while the mortality rate is projected to demonstrate a gradual decline.
conclusionIn high SDI regions, elderly males aged 75 and older are categorized as a high-risk group for urologic neoplasms. Smoking and elevated fasting plasma glucose levels are identified as the primary risk factors for bladder cancer, whereas obesity is recognized as the predominant risk factor for kidney cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.